| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 43.8 | 44.2 | 35.9 |
| Other income | 0.1 | 0.9 | 0.3 |
| Total income | 43.9 | 45.2 | 36.1 |
| Profit before exceptional items & tax | 15.2 | 14.3 | 12.1 |
| Profit before tax | 15.2 | 14.3 | 12.1 |
| Net profit | 11.1 | 10.9 | 9.1 |
| Operating margin | 34.6% | 31.6% | 33.5% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +22.00% |
|---|---|
| Net profit, quarter on quarter | +1.80% |
| Revenue, year on year | +22.00% |
| Operating profit, year on year | +28.00% |
| Operating profit, quarter on quarter | +12.70% |
BSE results filing, NSE: GUJTHEM. Figures extracted from the filing.
Gujarat Themis Biosyn Ltd: key numbers
- Share price
- ₹417.00
- Market cap
- ₹5,427 Cr
- Revenue (annual)
- ₹165.8 Cr
- Net profit (annual)
- ₹46.68 Cr
- P/E (TTM)
- 111.5×Sector 50.4×
- Promoter holding
- 59.33%-11.53% QoQ
- FII holding
- 4.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gujarat Themis Biosyn Ltd
All →Gujarat Themis Biosyn Annual General Meeting
Gujarat Themis Biosyn issued a corrigendum to its 45th AGM notice, updating the preferential issue resolution regarding share price, issue size, and allottee details.
Gujarat Themis Biosyn Acquisition Worth ₹1,300 Cr
Gujarat Themis Biosyn Limited acquired MicroBiopharm Japan Co. Ltd. for approximately ₹1,300 Crore. This acquisition expands its pharmaceutical CDMO capabilities.
- Value
- ₹1,300 Cr
Gujarat Themis Biosyn Dividend
Gujarat Themis Biosyn Limited has fixed September 23, 2026, as the record date for determining member entitlement for the final dividend for FY 2025-26.
Gujarat Themis Biosyn Acquisition Worth ₹1,333 Cr
GTBL completed 100% acquisition of MBJ Japan for JPY 21.5 billion (~₹1,333 Cr). The deal adds three GMP plants and precision fermentation capabilities.
- Value
- ₹1,333 Cr
- GMP-compliant manufacturing plants
- 3 plants
Gujarat Themis Biosyn Debt & Borrowing
Gujarat Themis Biosyn Limited announced the allotment of non-convertible debt securities. The filing serves as a regulatory disclosure regarding the issuance of these instruments.
Gujarat Themis Biosyn Other Announcement
Gujarat Themis Biosyn Ltd has submitted its quarterly shareholding pattern. This filing is a routine disclosure mandated by SEBI regulations.